ArticleFrontiers in neurology2025
Real world study in Italian public hospital with Efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of efgartigimod in myasthenia gravis: A meta-analysis of different antibody subtypes.Immunologic research · 2026Pooled it
- Real-world study of efgartigimod in AChR antibody-positive generalized myasthenia gravis: thymus status, multi-domain symptom improvement and steroid-sparing effect.Frontiers in immunology · 2026Article
- An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis.Drug design, development and therapy · 2026Observational
- Case Report: Use of telitacicept for ocular myasthenia gravis.Frontiers in immunology · 2026Article
- Efgartigimod-alfa therapy in acetylcholine receptor antibody myasthenia gravis: Romanian experience.Frontiers in neurology · 2026Article
- Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by IgG autoantibodies targeting the neuromuscular junction. Recycling of IgG is mediated by the neonatal Fc receptor (FcRn). Efgartigimod, an Fc fragment of human IgG1, has demonstrated efficacy in MG; however, the clinical characteristics of patients with the highest response remain unclear. Methods: Twelve patients with AChR-positive generalized MG were treated with two cycles of Efgartigimod over 1 year, and nine patients completed a third cycle. Clinical evaluation was conducted using MG-ADL at four time points and QMG at the beginning and end of each cycle. MG-ADL and QMG scores were further subdivided into ocular (O), bulbar (B), and generalized (G) symptom subdomains, and patients were classified as predominantly ocular (pO), bulbar (pB), or generalized (pG) based on symptom prevalence. Results: Significant improvements were observed in MG-ADL and QMG from baseline across all symptom subdomains. Baseline AChR antibody levels correlated with MG-ADL improvement ( Discussion: Our findings suggest that patients with high baseline AChR antibody titers, previous thymectomy, and non-ocular symptom predominance respond better to Efgartigimod. These results underscore the need for larger studies to validate these observations and optimize patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.